<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04604275</url>
  </required_header>
  <id_info>
    <org_study_id>20191253</org_study_id>
    <nct_id>NCT04604275</nct_id>
  </id_info>
  <brief_title>Functional Sucrase Deficiency in Short Bowel Syndrome Patients With Intestinal Failure</brief_title>
  <official_title>Functional Sucrase Deficiency in Short Bowel Syndrome Patients With Intestinal Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Miami</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>QOL Medical, LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Miami</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Short gut syndrome with intestinal failure patients may have decreased production of&#xD;
      disaccharidases, like sucrase, an enzyme responsible for digesting sugar in foods. This can&#xD;
      happen due to loss of bowel length from surgery or from loss of cellular function in the&#xD;
      intestines due to use of parenteral nutrition intravenously. Therefore, patients with these&#xD;
      conditions may not be able to digest sucrose (sugar) fully. Patients might experience&#xD;
      abdominal distension/pain, vomiting and diarrhea when sugar is taken in orally or through the&#xD;
      g-tube, which can limit patients' ability to increase oral or g-tube feeds in short gut&#xD;
      syndrome patients with intestinal failure.&#xD;
&#xD;
      In patients with short gut syndrome and intestinal failure, the administration of exogenous&#xD;
      sucrase (enzyme) may improve sucrose (sugar) digestion and thus the ability to tolerate more&#xD;
      oral or g-tube feeds.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2022</start_date>
  <completion_date type="Anticipated">November 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Carbohydrate Malabsorption</measure>
    <time_frame>baseline, up to 9 weeks</time_frame>
    <description>Degree of carbohydrate malabsorption will be assessed by decrease in number of stools per day.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Carbohydrate Malabsorption as measured by patient symptom survey</measure>
    <time_frame>baseline, up to 9 weeks</time_frame>
    <description>Degree of carbohydrate malabsorption will be assessed by change in patient symptomatology by change in score on patient symptom survey.&#xD;
The survey has range from 0-52 with higher score being worse symptoms and lower being better.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Carbohydrate Malabsorption as measured by growth velocity</measure>
    <time_frame>baseline, up to 9 weeks</time_frame>
    <description>Carbohydrate malabsorption will be measured by increase in growth velocity in kg/week</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Carbohydrate Malabsorption as measured by enteral nutrition tolerance</measure>
    <time_frame>baseline, up to 9 weeks</time_frame>
    <description>Carbohydrate malabsorption will be measured by ability to advance enteral nutrition in ml/day</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in digestion</measure>
    <time_frame>baseline, up to 9 weeks</time_frame>
    <description>Change in digestion will be measured by change in abdominal distension/girth measured in cm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in digestion as measured by amount of emesis</measure>
    <time_frame>baseline, up to 9 weeks</time_frame>
    <description>Change in digestion will be assessed by number of emesis per day</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in digestion as measured by stool consistency</measure>
    <time_frame>baseline, up to 9 weeks</time_frame>
    <description>Change in digestion will be assessed as a change in stool consistency from liquid (7) to solid(1) using Bristol stool chart</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Short Gut Syndrome</condition>
  <arm_group>
    <arm_group_label>Sucrase intervention followed by placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this arm will receive sucrase for 4 weeks followed by wash out of 1 week with no drug administered then 4 weeks of placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo followed by sucrase intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this arm will receive placebo for 4 weeks followed by wash out of 1 week with no drug administered then 4 weeks of sucrase.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sucrase</intervention_name>
    <description>1 mL (8,500 I.U.) (one full measuring scoop or 28 drops) per meal or snack for patients up to 15 kg in body weight. 2 mL (17,000 I.U.) for patients over 15kg in body weight. Dosage is 1 or 2 mL (8,500 to 17,000 I.U.) taken orally or by g-tube with each meal or snack diluted in water, milk, or infant formula.</description>
    <arm_group_label>Placebo followed by sucrase intervention</arm_group_label>
    <arm_group_label>Sucrase intervention followed by placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>1 mL of placebo per meal or snack for patients up to 15 kg in body weight. 2 mL of placebo per meal of snack for patients above 15kg in body weight. Dosage is 1 or 2 mL of placebo taken orally or by g-tube with each meal or snack diluted in water, milk, or infant formula.</description>
    <arm_group_label>Placebo followed by sucrase intervention</arm_group_label>
    <arm_group_label>Sucrase intervention followed by placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Short bowel syndrome, of all ages, with dependence on parental support to provide at&#xD;
             least 50% of fluid or caloric needs.&#xD;
&#xD;
          -  Must be on diet containing sucrose.&#xD;
&#xD;
          -  Must be willing and able to sign informed consent&#xD;
&#xD;
          -  Adult and Pediatric patients (all ages)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Current IV antibiotic administration for confirmed bout of bacteremia.&#xD;
&#xD;
          -  No enteral nutrition&#xD;
&#xD;
          -  Any condition, disease, illness, or circumstance that in the investigator's opinion&#xD;
             puts the subject at any undue risk, prevents completion of the study, or interferes&#xD;
             with analysis of the study results&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amanda Fifi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Miami</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amanda Fifi, MD</last_name>
    <phone>3052433166</phone>
    <email>afifi@med.miami.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Cara Axelrod, RD</last_name>
    <phone>3052433166</phone>
    <email>cxa630@med.miami.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Jackson Memorial Hospital</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Amanda Fifi, MD</last_name>
      <phone>305-243-3166</phone>
      <email>afifi@med.miami.edu</email>
    </contact>
    <contact_backup>
      <last_name>Cara Axelrod, MD</last_name>
      <phone>3052433166</phone>
      <email>cxa630@med.miami.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Amanda Fifi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Amanda Fifi, MD</last_name>
      <phone>305-243-3166</phone>
      <email>afifi@med.miami.edu</email>
    </contact>
    <contact_backup>
      <last_name>Cara Axelrod, RD</last_name>
      <phone>3052433166</phone>
      <phone_ext>FIFI</phone_ext>
      <email>amandacfifi@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>AMANDA FIFI, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>October 22, 2020</study_first_submitted>
  <study_first_submitted_qc>October 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 27, 2020</study_first_posted>
  <last_update_submitted>September 21, 2021</last_update_submitted>
  <last_update_submitted_qc>September 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Miami</investigator_affiliation>
    <investigator_full_name>Amanda Fifi</investigator_full_name>
    <investigator_title>Assistant Professor of Pediatrics</investigator_title>
  </responsible_party>
  <keyword>Intestinal failure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Short Bowel Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

